Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.

ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects children, is still a medical challenge, especially for refractory patients for whom therapeutic options are scarce. Recent advances in immunotherapy for B-cell malignancies based on increasingly efficacious monoclonal antibodies (mAbs) and chimeric antigen receptors (CARs) have been encouraging for non-responding or relapsing patients suffering from other aggressive cancers like T-ALL. However, secondary life-threatening T-cell immunodeficiency due to shared expression of targeted antigens by healthy and malignant T cells is a main drawback of mAb-or CAR-based immunotherapies for T-ALL and other T-cell malignancies. This review provides a comprehensive update on the different immunotherapeutic strat

SUBMITTER: Bayon-Calderon F 

PROVIDER: S-EPMC7589289 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature